WE ARE ENDECE
ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a biological response for a gain of function. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including multiple sclerosis (MS) and Alzheimer’s disease.
ENDECE was founded in 2006 and is headquartered in Mequon, Wisconsin.
NDC-1308 Timeline, Drug Approval Process. How close is NDC-1308 To The Clinic?read more
ENDECE to Present Data on NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis
ENDECE will present “NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis,” during two sessions of the American Academy of Neurology…read more